Sleep surgery society backs hypoglossal nerve stimulation; language models falter on complex ENT cases; new drug carries hearing loss warning

Listen to this post
read by AI voices · all episodesThe International Surgical Sleep Society issued a position statement concluding that hypoglossal nerve stimulation is safe and effective and should be part of comprehensive care for adult obstructive sleep apnea.
A study found large language models' diagnostic accuracy fell to 28.7% on complex otolaryngology cases. The Food and Drug Administration (FDA) approved intrathecal adrabetadex with a boxed warning for permanent hearing loss and said hearing should be evaluated before and during treatment.
- Guidelines Nov 16, 2026The International Surgical Sleep Society published a position statement in Otolaryngology-Head and Neck Surgery, drawing on data from 43 studies, concluding that hypoglossal nerve stimulation (HNS) is safe and effective and should be considered part of a comprehensive approach to managing obstructive sleep apnea in adults. The statement reported surgical response ranging from 67% to 83% and adherence of 5.6 to 7.7 hours a night. It said complications after HNS, while low, should be discussed with patients before implantation.Sources: Otolaryngology-Head and Neck Surgery, PubMed
- AI Nov 16, 2026A comparative study in Otolaryngology-Head and Neck Surgery tested three large language models on 80 outpatients from two centers and 40 published case reports. Claude-Sonnet-4.5 and Gemini-2.5-Pro significantly outperformed ChatGPT-5 on differential diagnosis, additional examinations, treatment and total score (P < .001). Primary diagnostic accuracy peaked at 54.6% for moderate cases and dropped to 28.7% for complex ones (P < .001). The authors said performance depended on prompt formulation and clinical complexity and stressed structured prompts and supervised clinical use.Sources: Otolaryngology-Head and Neck Surgery, PubMed
- FDA Nov 17, 2026The Food and Drug Administration (FDA) approved Lembaz (adrabetadex) for infantile-onset Niemann-Pick disease type C with a boxed warning for hearing impairment, including permanent hearing loss. The FDA said a comprehensive hearing evaluation should be performed before starting the drug and regularly during treatment, with possible dose adjustments; NeurologyLive reported baseline pure tone audiometry, speech recognition and tympanometry, with repeat evaluations one to two weeks after each dose at each dose level. Hearing loss has occurred in some patients with normal hearing before treatment, NeurologyLive reported.Sources: FDA, NeurologyLive
- Research Nov 19, 2026A retrospective TriNetX cohort study in JAMA Otolaryngology-Head & Neck Surgery of 4,532 adults with head and neck squamous cell carcinoma found that users of glucagon-like peptide-1 receptor agonists had better overall survival than controls at five years (adjusted hazard ratio 0.51, 95% CI 0.46 to 0.57). The association held in oral cavity, oropharynx and larynx subsites. The authors wrote that the findings suggest there may be survival benefits associated with the drugs.
The weekly innovation roundup for otolaryngology, published every Sunday for the week before; every item links to its sources. Latest otolaryngology news · All specialties